Literature DB >> 15020565

The use of maximum likelihood methods to estimate the risk of tuberculous infection and disease in a Canadian First Nations population.

Michael Clark1, Emilia Vynnycky.   

Abstract

BACKGROUND: Tuberculosis (TB) notification rates among First Nations people in British Columbia, Canada, are higher than those among non-First Nations people, although rates are declining more rapidly in the First Nations population. The epidemiology of tuberculous infection and disease during the period 1926-2000 in this population was investigated.
METHODS: The trend in the annual risk of infection (ARI) since 1926 was estimated using tuberculous meningitis mortality statistics and skin testing data. Risks of progression from infection to disease were estimated by fitting model predictions of disease incidence to TB notifications, using maximum likelihood methods. Infectious TB notifications were matched with ARI estimates to obtain the number of transmissions per infectious case over time.
RESULTS: We estimate that the ARI decreased from more than 10% during the prechemotherapy era to less than 0.1% by 2000. The risks of primary, reactivation, and exogenous re-infection disease among adults aged 25-44 years were 22%, 0.1%, and 6%, respectively. The number of transmissions per infectious case decreased from 16 to 2 from the early 1970s to the late 1990s.
CONCLUSIONS: This study shows that the risk of infection among British Columbia First Nations people is decreasing, while the relative contribution of reactivation to disease incidence is increasing. Once infected, First Nations people may have a higher risk of developing disease than other populations.

Entities:  

Mesh:

Year:  2004        PMID: 15020565     DOI: 10.1093/ije/dyh001

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  9 in total

Review 1.  Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis.

Authors:  Jason R Andrews; Farzad Noubary; Rochelle P Walensky; Rodrigo Cerda; Elena Losina; C Robert Horsburgh
Journal:  Clin Infect Dis       Date:  2012-01-19       Impact factor: 9.079

2.  Dynamical Modeling as a Tool for Inferring Causation.

Authors:  Sarah F Ackley; Justin Lessler; M Maria Glymour
Journal:  Am J Epidemiol       Date:  2022-01-01       Impact factor: 5.363

3.  Tuberculosis control in South African gold mines: mathematical modeling of a trial of community-wide isoniazid preventive therapy.

Authors:  Emilia Vynnycky; Tom Sumner; Katherine L Fielding; James J Lewis; Andrew P Cox; Richard J Hayes; Elizabeth L Corbett; Gavin J Churchyard; Alison D Grant; Richard G White
Journal:  Am J Epidemiol       Date:  2015-03-19       Impact factor: 4.897

4.  Modeling historical tuberculosis epidemics among Canadian First Nations: effects of malnutrition and genetic variation.

Authors:  Sarah F Ackley; Fengchen Liu; Travis C Porco; Caitlin S Pepperell
Journal:  PeerJ       Date:  2015-09-24       Impact factor: 2.984

5.  Making wider use of the world's most widely used vaccine: Bacille Calmette-Guerin revaccination reconsidered.

Authors:  Christopher Dye
Journal:  J R Soc Interface       Date:  2013-07-31       Impact factor: 4.118

6.  Modelling heterogeneity in host susceptibility to tuberculosis and its effect on public health interventions.

Authors:  Isaac Mwangi Wangari; James Trauer; Lewi Stone
Journal:  PLoS One       Date:  2018-11-14       Impact factor: 3.240

7.  Risk factors for tuberculosis.

Authors:  Padmanesan Narasimhan; James Wood; Chandini Raina Macintyre; Dilip Mathai
Journal:  Pulm Med       Date:  2013-02-12

8.  The benefits and risks of bacille Calmette-Guérin vaccination among infants at high risk for both tuberculosis and severe combined immunodeficiency: assessment by Markov model.

Authors:  Michael Clark; D William Cameron
Journal:  BMC Pediatr       Date:  2006-03-03       Impact factor: 2.125

9.  Impact of latent infection treatment in indigenous populations.

Authors:  Lucia Suemi Yuhara; Flávia Patussi Correia Sacchi; Julio Croda
Journal:  PLoS One       Date:  2013-07-31       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.